![](https://webarchive.library.unt.edu/eot2008/20081024092700im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081024092700im_/http://www.cancer.gov/images/spacer.gif)
ticilimumab A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Ticilimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20081024092700im_/http://www.cancer.gov/images/spacer.gif)
Synonym: | ![](https://webarchive.library.unt.edu/eot2008/20081024092700im_/http://www.cancer.gov/images/spacer.gif) | anti-CTLA4 human monoclonal antibody CP-675,206 | | ![](https://webarchive.library.unt.edu/eot2008/20081024092700im_/http://www.cancer.gov/images/spacer.gif) | Code name: | ![](https://webarchive.library.unt.edu/eot2008/20081024092700im_/http://www.cancer.gov/images/spacer.gif) | CP-675,206 | | ![](https://webarchive.library.unt.edu/eot2008/20081024092700im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081024092700im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081024092700im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081024092700im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081024092700im_/http://www.cancer.gov/images/spacer.gif) |